Pathfinder Cell Therapy (Pathfinder Cell Therapy) Growth Rank : 0 (As of Jun. 07, 2024)

View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Growth Rank?

Pathfinder Cell Therapy has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Pathfinder Cell Therapy Growth Rank Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Bow Street, Cambridge, MA, USA, 02138

Website

http://www.pathfindercelltherapy.com

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.

Executives

John J Alam	director	130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines